Shares of Trius Therapeutics Shares Rise 2% After-Hours on Jim Cramer's Interview with CEO Jeff Stein
July 11, 2013 at 20:02 PM EDT
Shares of Trius Therapeutics (NASDAQ: TSRX ) rose 9.5% Thursday and another 2% after-hours, as Jim Cramer interviewed the company's CEO Jeff Stein. Trius' drug Tedizolid has completed the phase 3 clinical trial for the treatment of acute bacterial skin and skin structure infections. FDA approval is expected by
